Member Info for EmeraldCarrots

.

Weeks/months. The Illumina web site lists partners they have in the industry, for example:-

https://emea.illumina.com/destination/onctargetedpanels.html?media=9089155&utm_medium=paidsearch&catt=paidsearch_Google_Ads_Search&gad_source=1&gclid=EAIaIQobChMI5Lnb-pLGiwMVMJRQBh1qcCVtEAAYASAAEgIoG_D_BwE

If you click on the "Liquid Biopsy Panels" Tab, it shows they Partner this "Pillar Biosciences" company.

Obviously, Illumina’s web site will need a way to navigate to get the new "Dual Analysis" (CtDna and CTC analysis) Angle now offer using Illumina’s lung cancer panel. Not sure how this will turn out but clearly Illumina will want to promote their lung cancer panel (as referred to in Angle's RNS) and the new panels as they become available (Breast, Ovarian etc..).

Likewise Angle’s WEB site will need to be updated to show the “CTC DNA / ctDNA combined profiling” is now available for lung cancer. At the moment it says “Additional assays currently in development:”.

It strikes me the above has not happened yet as Angle are no doubt talking to Illumina still.................. Big news to come I think.

All IMHO.

To be honest I am very concerned we have heard next to nothing. What on Earth have they been doing? News soon???

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Ss in a total panic now. Hilarious!

Sympathy for their massive losses that are IMHO inevitable once the Illumina tie up blossoms. Updates on Illumina and Angle's web sites for starters. Then we will no doubt get news on more Illumina assay panels to compliment the existing lung cancer one.......... Angle's sp is going to Rocket.

All IMHO.

(as compared to just CtDna analysis) in any lung cancer patient using the new dual analysis or not? The answer seems all too obvious. Sp here is going to ROCKET.

All IMHO.

Looking back at your posts you have added zero to the discussion. NOTHING. Have a look. No interesting points about the RNS's, no links to interesting news about liquid biopsies, no explanations to help people understand what the difference is between CtDna analysis and CTC analysis actually is. IMHO your posts to date have been a waste of time. You may even be TwoGood2Die who is completely panic stricken about the Illumina tie up that will only be gathering pace. I suspect TwoGood has a huge, short on AGL. That is the only plausible explanation.

All IMHO.

Https://emea.illumina.com/destination/onctargetedpanels.html?media=9089155&utm_medium=paidsearch&catt=paidsearch_Google_Ads_Search&gad_source=1&gclid=EAIaIQobChMI5Lnb-pLGiwMVMJRQBh1qcCVtEAAYASAAEgIoG_D_BwE

No prises for for the next one to be added to the list very soon IMHO. I'll give you a clue:-

https://www.lse.co.uk/rns/AGL/analysis-of-ctc-dna-and-ctdna-using-illumina-assay-mqynkijrkyza9ga.html

All IMHO.

Done my homework. More than 50% of shares need to be controlled by the major shareholders to stop a bid. Of course they would need to be in agreement to achieve this. Interesting. So, the likes of Illumina, Thermo Fisher, Eisai and Astrazeneca could attempt a takeover without the backing of the board, and the major shareholders could not stop it (Total: 22.81%) as long as more than 50% of the other share holders agree it......... Fireworks in the future here I suspect!

All IMHO.

Major shareholders.

Dermot Keane 12/07/2024

26,110,422 8.09%

Conifer Management LLC 05/09/2024

25,376,217 7.87%

Global Frontier Partners, LP 17/07/2024

22,088,947 6.85%

=================

Total: 22.81%.

Not enough to be sure of blocking a takeover. I think that would be 30%?

? as the AIM rules say any bid has to be more than the max sp in the previous 12 months (was 19p a share in Feb 2024). Would the other major share holders go for this?

Tick up @ 1pm.

Co, now backing Angle!! LOL! Fat chance IMHO. However the green boxes with the likes of researcher1, Bankruptstock, Popeye62, Guy_incognito, robizm1001, Moab, TwoGood2Die and GordonGecko123 **have magically re-appeared**. Maybe they are a gang?? I'm wondering if this is in fact the case?

Is very real as confirmed in the RNS. Having possibly the worlds Nr1 DNA analysis Company (market cap 21 Billion $) helping promote Angles new dual analysis will be transformational for Angle in due course. Analysis which has been shown to DOUBLE the chances of finding targetable biomarkers in a person’s cancer. Biomarkers can be targeted by modern cancer drugs. It could hardly be better.

Then we have the prospect of updates on the two Astrazeneca contracts and the Eisai one.

Plus, numerous other potential money spinners, too many to list.

Personally, I think the next big RNS will be a new contract to monitor CTC's before, during and after a phase ii cancer drug trial. Once a few like this break I expect this revenue source to snowball.

I am very happy with my investment.

Also, of course, the prospect of a bid is very real indeed,

All IMHO.

Has the penny dropped with the bigger players? Maybe they needed some meetings first? How ridiculous.

Loads of buys coming in, have a look.

Co. finally being taken on board by the S L O W market? About time!

Tick up.

Stranger things have happened I suppose!

New Angle/Illumina dual CtDna & CTC analysis, giving TWICE the chance of finding a cancers TARGETABLE biomarker may want more than the one machine. If some of these companies currently offer CtDna analysis throughout the USA and beyond they may have 10, 20, 30 or more of Illumina’s machines to do the DNA analysis. There is massive demand for the CtDna analysis as we know. So, some of these Companies may want to buy half a dozen or more Parsortix machines.

I'm telling you the market is ASLEEP, TOTALLY. You will see when the penny drops.

All IMHO.